Diabetes Archives

News and Trends 13 Mar 2015

Orgenesis acquires MaSTherCell

Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities. The American and the Belgian companies have already been working jointly since last year to scale manufacturing of Orgenesis’ insulin-producing liver cells to fight diabetes. […]

March 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Feb 2015

Sanofi: Get Ready for the Launch of the First Inhaled Insulin in the U.S.

Sanofi, the global healthcare leader has core strengths in the field of healthcare due to its seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. This article will focus on Sanofi Diabetes. In August 2014, our previous article “Sanofi buys Mannkind’s inhaled insulin for €824.5m” […]

February 27, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 21 Feb 2015

Succesfull Phase II for Novo Nordisk’s new diabetes treatment

Good news for diabetes mellitus type 2 patients, as Novo Nordisk announced positive results for phase II trial with oral semaglutide. Novo Nordisk successfully completed the phase II trial for OG217SC, an oral formulation of the longacting GLP-1 analogue semaglutide. Confirming the primary end-point of the trial, all doses of oral semaglutide were statistically significantly […]

February 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Nov 2014

Novo Nordisk invests €104M in new laboratory for Diabetes

Danish insulin giant Novo Nordisk has made a 104 million euros investment in new laboratories at the company’s research and development campus. Based in Malov in Denmark, the lab is expected to be ready for occupation in early 2016. The new facility, Diabetes Research House, will accommodate approximately 350 employees. During the construction phase, the project […]

November 4, 2014 - 1 minutemin - By Julie Lellouche

Oral Insulin All Mouth or an Injection of Hope for Type 1 Diabetes medium vga

News and Trends 8 Oct 2014

Once a Week Insulin Shot : Novo Nordisk’s new Idea

Denmark’s Novo Nordisk, the world’s largest insulin seller, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world’s first once-weekly insulin injection. Almost 592 million people are expected to live with diabetes by 2035, up 55 percent from last year’s level, according to the International Diabetes […]

October 8, 2014 - 2 minutesmins - By Julie Lellouche

Eli Lilly and Boehringer Ingelheim’s product the first insulin biosimilar approved in Europe2

News and Trends 16 Sep 2014

The first insulin biosimilar has been approved in Europe

The European Commission granted marketing authorisation to Eli Lilly and Company and Boehringer Ingelheim for the first insulin biosimilar glargine product. It is indicated to treat diabetes in adults, adolescents and children aged 2 years and above. The collaboration between the two companies is bearing fruit, it is the first-ever version of this class. It received […]

September 16, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Aug 2014

Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment

Adocia announced today the initiation of a clinical Phase III study in India of BioChaperone PDGF-BB, the company’s innovative formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of diabetic foot ulcers. This follows the approval given by the Drug Controller General of India (DCGI) on August 22nd, 2014. The dossier for this clinical […]

August 26, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 25 Aug 2014

KalVista start the clinical development of a new treatment for diabetic macular edema

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study’s principal investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin Diabetes Center. […]

August 25, 2014 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us